Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...

The two companies, along with 17 US health systems, will collectively take a $320 million stake in Truveta, with Regeneron ...

Over more than eight years of monitoring, getting familiar with the EU CTR, conducting trial submissions activities, etc., ...

But for an industry in which 46 recalls is 46 too many, given the potentially immense costs these incidents can exact, the ...

We’ll hear from speakers representing Syneos Health, Flagship Pioneering, and IPSEN on pharma dealmakers’ 2025 intentions, ...

And yet, data science is now poised to usher in a level and acceleration of progress that even life sciences have never ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma ...

Each year at the JP Morgan Healthcare Conference, life sciences leaders congregate in San Francisco’s Union Square to network ...

This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, ...

Solution: EVERSANA created an AI-enabled omnichannel solution to inform and empower HCPs and patients more effectively. The ...

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...